<DOC>
	<DOCNO>NCT01856478</DOCNO>
	<brief_summary>This randomize , open-label , phase III study perform patient recurrent and/or metastatic head neck cancer progress platinum-based therapy . The objective trial compare efficacy safety afatinib versus methotrexate .</brief_summary>
	<brief_title>LUX-Head &amp; Neck 3 : Afatinib ( BIBW2992 ) Versus Methotrexate Treatment Recurrent and/or Metastatic Head Neck Squamous Cell Cancer After Platinum Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Inclusion criterion : 1 . Histologically cytologically confirm squamous cell carcinoma oral cavity , oropharynx , hypopharynx larynx , recurred/metastasised amenable salvage surgery radiotherapy . 2 . Documented progressive disease base investigator assessment accord RECIST , follow receipt cisplatin and/or carboplatin and/or Nedaplatin base regimen administer recurrent and/or metastatic disease independent whether patient progress platinum base therapy . 3 . Measurable disease accord RECIST ( version 1.1 ) . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Visit 2 . 5 . Male female patient age 18 year old 6 . Signed date write informed consent compliance ICHGCP local law . Exclusion criterion : 1 . Progressive disease within three month completion curatively intend treatment locoregionally advance metastatic head neck squamous cell cancer ( HNSCC ) . 2 . Primary tumour site nasopharynx ( histology ) , sinuses , and/or salivary gland . 3 . Any one previous platinum base systemic regimen give recurrent and/or metastatic disease . Rechallenge first line regimen temporary break consider second line regimen case progression within break . 4 . Prior treatment EGFRtargeted small molecule . 5 . Treatment investigational drug less four week anticancer therapy less three week prior randomization ( except palliative radiotherapy bone alleviate pain ) . 6 . Unresolved chronic toxicity , hear loss , tinnitus dry mouth , CTCAE grade &gt; 2 previous anticancer therapy unresolved skin toxicity CTCAE grade &gt; 1 and/or diarrhoea CTCAE grade &gt; 1 cause prior treatment EGFR target antibody . 7 . Previous tumour bleed CTCAE grade =3 . 8 . Requirement treatment prohibit concomitant medication . 9 . Major surgical plan procedure less four week prior randomization ( isolated biopsy consider major surgical procedure ) . 10 . Any malignancy unless free disease least five year except : 1 . Other HNSCC location describe inclusion criterion number 1 2 . Appropriately treated superficial basal cell skin cancer 3 . Surgically cured cervical cancer situ 4 . For Korea : endoscopically cure superficial esophageal and/or gastric cancer allow 11 . Known lesion sign brain metastasis . 12 . Known preexist interstitial lung disease ( ILD ) . 13 . Clinically relevant cardiovascular abnormality , judge investigator , , limit , uncontrolled hypertension , congestive heart failure NYHA classification =III , unstable angina , myocardial infarction within six month prior randomization , poorly control arrhythmia . 14 . Cardiac leave ventricular dysfunction rest ejection fraction &lt; low limit normal ( LLN ) investigational site ( LLN define site lower limit 50 % ) . 15 . Significant recent acute gastrointestinal disorder diarrhoea major symptom opinion investigator , e.g . Crohn 's disease , malabsorption CTCAE grade &gt; 1 diarrhoea aetiology randomization . 16 . Known HIV , active hepatitis B , active hepatitis C , and/or know severe infection , include limited tuberculosis , judge investigator . 17 . Other significant disease investigator 's opinion would exclude subject trial . 18 . Screening laboratory value : 1 . Absolute neutrophil count ( ANC ) &lt; 1.5x10^9/l 2 . Platelet count &lt; 75x10^9/l 3 . Total bilirubin &gt; 1.5 time upper limit normal ( ULN ) 4 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) &gt; 3 time ULN ( relate liver metastases &gt; 5 time ULN ) 5 . Calculated creatinine clearance &lt; 50 ml/min ( evidence use CockcroftGault formula ) . 19 . Women childbearing potential men able father child , unwilling abstinent use adequate contraception trial least six month end treatment . Adequate method contraception definition childbearing potential . 20 . Pregnancy breast feed . 21 . Known suspected hypersensitivity study medication excipients . 22 . Any past present history areca/betelnut chew derivative cumulative duration 3 month 23 . Patients unable comply protocol , opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>